Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Taysha Gene Therapies (Nasdaq: TSHA) announced that on October 1, 2025 its Compensation Committee granted inducement stock options to seven new employees totaling 1,289,600 shares under the 2023 Inducement Plan in accordance with Nasdaq Listing Rule 5635(c)(4).
The options carry an exercise price of $3.18 (equal to the closing price on the grant date), a 10-year term, and vest over four years (25% after one year, then monthly ratable vesting over 36 months), subject to continued service.
Taysha Gene Therapies (Nasdaq: TSHA) ha annunciato che, il 1 ottobre 2025, il suo Compensation Committee ha concesso stock option di indennità a sette nuovi dipendenti per un totale di 1.289.600 azioni nell'ambito del Piano di Induzione 2023, ai sensi della Nasdaq Listing Rule 5635(c)(4).
Le opzioni prevedono un prezzo di esercizio di $3,18 (uguale al prezzo di chiusura nel giorno della concessione), una durata di 10 anni, e si maturano su quattro anni (25% dopo un anno, poi maturazione mensile pro rata nei 36 mesi), soggetto a continuativa attività.
Taysha Gene Therapies (Nasdaq: TSHA) anunció que el 1 de octubre de 2025 su Comité de Compensación otorgó opciones de acciones por inducción a siete nuevos empleados por un total de 1.289.600 acciones bajo el Plan de Inducción 2023, de conformidad con la Regla 5635(c)(4) de Nasdaq Listing.
Las opciones tienen un precio de ejercicio de $3.18 (igual al precio de cierre en la fecha de concesión), un plazo de 10 años, y se consolidan durante cuatro años (25% tras un año, luego consolidación mensual prorrateada durante 36 meses), sujeto a continuar prestando servicios.
Taysha Gene Therapies (Nasdaq: TSHA)는 2025년 10월 1일에 보상 위원회가 지명 유도(inducement) 주식 옵션을 7명의 신규 직원에게 부여했다고 발표했습니다. 총 1,289,600주로 2023 Inducement Plan에 따라 Nasdaq Listing Rule 5635(c)(4)에 따라 부여되었습니다.
옵션의 행사가격은 $3.18이며(부여일의 종가와 동일), 유효기간 10년, 그리고 4년에 걸쳐 가상/지속 vesting 된다(1년 후 25%, 이후 36개월 동안 매월 비례 vesting), 지속 근무 조건하에.
Taysha Gene Therapies (Nasdaq: TSHA) a annoncé que, le 1er octobre 2025, son comité de rémunération a accordé des options d'inductions à sept nouveaux employés pour un total de 1 289 600 actions dans le cadre du Plan d'Induction 2023, conformément à la Règle de cotation Nasdaq 5635(c)(4).
Les options comportent un prix d'exercice de 3,18 $ (identique au prix de clôture à la date d'octroi), une durée de 10 ans, et se vissent sur quatre ans (25 % après un an, puis vesting mensuel au prorata sur 36 mois), sous réserve de l'emploi continu.
Taysha Gene Therapies (Nasdaq: TSHA) gab bekannt, dass am 1. Oktober 2025 sein Vergütungsausschuss Induzierungs-Aktienoptionen an sieben neue Mitarbeitende im Rahmen des 2023 Inducement Plans gemäß Nasdaq Listing Rule 5635(c)(4) gewährt hat, in Gesamtbetrag von 1.289.600 Aktien.
Die Optionen haben einen Ausübungspreis von 3,18 $ (entsprechend dem Schlusskurs am Gewährungstag), eine Laufzeit von 10 Jahren und vesten über vier Jahre (25% nach dem ersten Jahr, danach monatlich anteilig über 36 Monate), vorbehaltlich fortgesetzter Tätigkeit.
Taysha Gene Therapies (Nasdaq: TSHA) أعلنت أن لجنة التعويضات لديها في 1 أكتوبر 2025 قد منحت خيارات أسهم تحفيزية لسبعة موظفين جدد بإجمالي 1,289,600 سهم بموجب خطة التحفيز لعام 2023 وفقًا لـ قاعدة إدراج Nasdaq 5635(c)(4).
تتضمن الخيارات سعر تمارين قدره 3.18 دولارات (يساوي سعر الإغلاق في تاريخ المنح)، و مدة صلاحية 10 سنوات، وتتحدد خلال أربع سنوات (25% بعد السنة الأولى، ثم vesting شهريًا بالتناسب خلال 36 شهراً)، شرط الاستمرار بالخدمة.
Taysha Gene Therapies (Nasdaq: TSHA)宣布其薪酬委员会于2025年10月1日日向七名新员工授予诱导性股票期权，总计1,289,600股，依据2023年诱导计划及纳斯达克上市规则5635(c)(4)执行。
这些期权的行权价为$3.18（等于授予日的收盘价）、10年期限，并在四年内逐步归属（在第一年后归属25%，随后在36个月内按月等额归属），前提是持续为公司服务。
- None.
- None.
DALLAS, Oct. 03, 2025 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced that, on October 1, 2025, the Compensation Committee of Taysha's Board of Directors granted seven new employees, in the aggregate, options to purchase 1,289,600 shares of the Company's common stock in connection with their employment. The stock options were granted under the Taysha Gene Therapies, Inc. 2023 Inducement Plan as an inducement material to the individuals entering employment with Taysha in accordance with Nasdaq Listing Rule 5635(c)(4).
The stock options have an exercise price of
About Taysha Gene Therapies
Taysha Gene Therapies (Nasdaq: TSHA) is a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system. Its lead clinical program TSHA-102 is in development for Rett syndrome, a rare neurodevelopmental disorder with no approved disease-modifying therapies that address the genetic root cause of the disease. With a singular focus on developing transformative medicines, Taysha aims to address severe unmet medical needs and dramatically improve the lives of patients and their caregivers. The Company’s management team has proven experience in gene therapy development and commercialization. Taysha leverages this experience, its manufacturing process and a clinically and commercially proven AAV9 capsid in an effort to rapidly translate treatments from bench to bedside. For more information, please visit http://www.tayshagtx.com.
Company Contact:
Hayleigh Collins
Senior Director, Corporate Communications and Investor Relations
Taysha Gene Therapies, Inc.
hcollins@tayshagtx.com
Media Contact:
Carolyn Hawley
Inizio Evoke
Carolyn.hawley@inizioevoke.com
FAQ
What did Taysha (TSHA) announce on October 1, 2025?
What is the exercise price and term for the TSHA inducement options?
How do the TSHA options vest and when does vesting start?
Under what plan were the TSHA inducement options granted?
Why did Taysha use Nasdaq Listing Rule 5635(c)(4) for these grants?
How many employees received inducement options in the TSHA announcement?
